These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29696160)

  • 41. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies.
    Yin J; Shen S
    J Biom Biostat; 2016 Dec; 7(4):. PubMed ID: 28616356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.
    Doussau A; Geoerger B; Jiménez I; Paoletti X
    Contemp Clin Trials; 2016 Mar; 47():217-27. PubMed ID: 26825023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.
    Polley MC; Cheung YK
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
    Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
    Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
    Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
    Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.
    Lin R; Zhou Y; Yan F; Li D; Yuan Y
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33283133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.
    Yan F; Mandrekar SJ; Yuan Y
    Clin Cancer Res; 2017 Aug; 23(15):3994-4003. PubMed ID: 28546227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interval design to identify the optimal biological dose for immunotherapy.
    Park Y
    Contemp Clin Trials Commun; 2022 Dec; 30():101005. PubMed ID: 36186542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should the choice of BOIN design parameter
    Lu R
    medRxiv; 2024 Mar; ():. PubMed ID: 38496500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An integrated dose-finding tool for phase I trials in oncology.
    Yang S; Wang SJ; Ji Y
    Contemp Clin Trials; 2015 Nov; 45(Pt B):426-434. PubMed ID: 26419937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.
    Cai C; Yuan Y; Ji Y
    J R Stat Soc Ser C Appl Stat; 2014 Jan; 63(1):159-173. PubMed ID: 24511160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A curve free Bayesian decision-theoretic design for phase Ia/Ib trials considering both safety and efficacy outcomes.
    Fan S; Lee BL; Lu Y
    Stat Biosci; 2020 Jul; 12(2):146-166. PubMed ID: 33815623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.
    Wages NA; Slingluff CL; Petroni GR
    Contemp Clin Trials; 2015 Mar; 41():172-9. PubMed ID: 25638752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.
    Sato H; Hirakawa A; Hamada C
    Stat Med; 2016 Oct; 35(23):4093-109. PubMed ID: 27221807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.
    Mandrekar SJ; Cui Y; Sargent DJ
    Stat Med; 2007 May; 26(11):2317-30. PubMed ID: 17016867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accelerated titration designs for phase I clinical trials in oncology.
    Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
    J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The rapid enrollment design for Phase I clinical trials.
    Ivanova A; Wang Y; Foster MC
    Stat Med; 2016 Jul; 35(15):2516-24. PubMed ID: 26833922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.